Wandercraft secures €25 million in financing from the European Investment Bank to advance self-balancing exoskeleton development

French medical robotics company Wandercraft has secured €25 million in financing from the European Investment Bank (EIB) to develop a personal self-balancing exoskeleton for people with severe mobility impairments and to accelerate patient access to Atalante X. The loan is guaranteed under the EU's InvestEU program. Atalante X has entered nearly 100 rehabilitation institutions and clinical research centers in Europe and the US, and has received FDA clearance for stroke and T5 to L5 spinal cord injury patients.